Causes of Major Tablet Defects

Capping and Lamination

Capping is typically caused by air entrapment in the granules or improper compression settings. High turret speeds, insufficient pre-compression, and low moisture content can aggravate the issue. Lamination, often confused with capping, results from weak interparticulate bonding during compression.

Explore the full topic: Manufacturing Defects

Sticking and Picking

These defects are common with hygroscopic or over-wet granules. Sticking is often due to inadequate lubrication or poor punch surface finishing. Picking tends to occur with tablets bearing logos or deeply engraved punches.

Weight Variation

Weight variation stems from non-uniform granule flow, improper feeder settings, or worn turret cams. It can also indicate blend segregation or poor granule density uniformity.

Friability and Breakage

These indicate poor mechanical strength and may result from inadequate binder, low compression force, or poorly formed granules. Oversized particles and lack of uniform mixing can also contribute.

Understanding these root causes is essential for establishing preventive controls. For example, a tablet compression SOP should define process parameters, tooling inspection frequency, and lubricant checks.

Regulatory Considerations for Tablet Quality

Tablet defects fall under the scope of CGMP requirements as per USFDA, EMA, and WHO guidelines. Regulatory bodies expect manufacturers to demonstrate control over critical process parameters (CPPs) that impact critical quality attributes (CQAs) like tablet hardness, weight, and appearance.

• 21 CFR Part 211 mandates in-process controls and batch uniformity.
• WHO TRS 986 emphasizes equipment qualification and preventive maintenance.
• EMA GMP Annex 15 requires validation of critical manufacturing steps including compression.

Failure to control tablet defects can trigger warning letters, product recalls, or import alerts. Hence, it is essential to document root cause investigations, implement CAPA, and revise operational procedures accordingly. Refer to Pharma GMP resources for templates on CAPA and deviation management.

Best Practices to Prevent Tablet Defects

Preventing tablet manufacturing defects involves a combination of formulation control, equipment setup, environmental monitoring, and personnel training. Here are actionable best practices:

1. Granulation Quality: Ensure consistent moisture content, granule size distribution, and drying profiles. Monitor binder ratios and use sieve analysis regularly.
2. Lubrication: Use the correct type and quantity of lubricant (e.g., magnesium stearate). Avoid over-lubrication as it may reduce tablet hardness and cause friability issues.
3. Compression Parameters: Calibrate compression force, pre-compression settings, and dwell time. Avoid operating at the high end of speed tolerance without validation.
4. Tooling Maintenance: Inspect punches and dies before every batch. Replace worn tooling and polish punches to prevent sticking and picking.
5. Environmental Controls: Maintain ideal humidity and temperature in the compression room. Hygroscopic materials are prone to sticking under high humidity.
6. In-Process Checks: Implement robust IPC protocols including weight variation, hardness, thickness, and visual inspection at defined intervals.
7. Training and Documentation: Ensure operators are trained to detect early signs of defects. Document every incident and link to root cause and CAPA plans.

As per validation best practices, all preventive strategies should be validated during process qualification batches.

Case Example: Tackling Capping in a High-Speed Compression Line

A generic pharma company faced batch rejections due to capping at turret speeds above 35 RPM. Investigation revealed poor granule compressibility and insufficient pre-compression force. The resolution involved adjusting the binder level in granulation, optimizing pre-compression force, and switching to flat-faced punches. Subsequent PPQ batches showed no capping. The company also updated their regulatory dossier with revised process parameters to maintain compliance.

Conclusion

Tablet manufacturing defects are a leading cause of batch failures in the pharmaceutical industry. By proactively understanding their root causes and applying best practices in formulation, equipment handling, and environment control, manufacturers can drastically reduce these issues. A preventive mindset supported by robust documentation, continuous training, and adherence to regulatory standards ensures that solid oral dosage forms meet quality expectations batch after batch.

Further reading: Explore stability testing impact on tablet quality and how formulation changes influence defect profiles during shelf life.